1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Cochlear Ltd.

Diggory Howitt

1 University Avenue
Macquarie University
Sydney, New South Wales 2109
Phone: 61294286555


Cochlear goes ex-dividend on Monday
Sep 14, 2023 15:31pm

Cochlear (CHEOY) had declared $1.75/share final dividend.

Source:Seeking Alpha
The Monday Report – 21 August 2023
Aug 20, 2023 22:57pm

By Greg Peel Choosing to Follow On It was a rock’n’roll session on the ASX200 on Friday, ahead of a flat close. The futures had said down -28 on Wall Street weakness, the ASX200 fell -22 points on the open, but by 12.30pm was up 21. Then it sold off in the afternoon. The market appeared to largely ignore Wall Street and concentrate on earnings results, although the 12.30pm pivot may have been as a result of the Japanese CPI coming in unchanged at 3.3% when 2.5% was forecast. Friday’s was only a smallish list of reporting companies, compared to Thursday’s extensive list, thus while there were some sharp moves for Friday’s reporters, more notable were follow-on moves from Thursday’s reports, post broker analysis. Magellan Financial ((MFG)) was the big winner among the Friday crowd with a 13.3% gain, after announcing a special dividend and cost cutting. Property Fund manager Centuria Capital ((CNI)) went the other way, falling -5.9%. Yet the real estate sector won the day with a 1.7% gain, thanks to a whopping follow-on surge for Goodman Group ((GMG)), up 7.3% on analyst assessments.

Cochlear™ Osia® System becomes industry''s first active bone conduction system to enable MRI at 3 Tesla
Aug 18, 2023 18:05pm

The new Osia ® System with Osia OSI300 Implant enables patients to undergo MRI at 3.0 Tesla (T) without the need for surgery This has been made possible by the OSI300''s unique Piezo Power™ technology and next-generation 3.0 T magnet technology The Osia System, which launched commercially in 2020, is indicated for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD) LONE TREE, Colo. , Aug. 18, 2023 /PRNewswire/ -- Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces its next generation Cochlear ™ Osia ® System with the ability to have an MRI at 3.0 T, designed to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD). The new Osia® System with Osia OSI300 Implant enables patients to undergo MRI at 3.0 T without the need for surgery. The new Osia System offers the proven benefits as the current version: excellent hearing outcomes 1 , ease of use, discreetness and reliability 2 .

Cochlear reports FY results
Aug 15, 2023 14:07pm

Cochlear press release (CHEOF): FY 2023 sales revenue increased 19% to a record $1,956 million, with strong growth across all business units.Statutory net profit increased 4% to…

Source:Seeking Alpha
Healthcare giants CSL, Cochlear lift ASX
Aug 15, 2023 06:49am

Healthcare stocks rallied 3.2 per cent, sending the benchmark S&P/ASX 200 Index up 28 points, or 0.4 per cent, to 7305.

Source:The Australian Financial Review
China and India are very important markets for Cochlear: CEO
Aug 15, 2023 06:29am

Dig Howitt, CEO and President of Cochlear, shares the company''s growth strategy in Asia.

ASX Large Caps: Local bourse up as China cuts key rate; aftermarket stock GUD top gainer, up by 15pc
Aug 15, 2023 06:07am

ASX pushed higher after earnings reports by majors Cochlear, CSL, and Seek reported results today In a surprising move, China’s central bank PBOC cuts its key lending rates The ASX 200 gained around 0.3% on Tuesday after a slew of earnings reports pushed the local bourse higher. Healthcare was the best performing sector, up by 3%, driven by a 5% lift from sector leader CSL (ASX:CSL) – more details below. The Tech sector also gained almost 2%, mostly driven by sentiment as Nasdaq and Mega Techs rose overnight. More bad news, however, for iron ore miners, with futures in Singapore trading below $US100 a tonne to near the lowest level since June. Oil stocks were also sold down as crude prices slipped by 1% overnight on concerns around the health of China and appreciation of the USD. And there was more bad news from China today, with July industrial output and retail sales growth coming in below forecasts. In a surprising move, China’s central bank PBOC unexpectedly cut its rates by 15bp this afternoon in response to the deteriorating data.

Cochlear investors hear siren call of higher profits
Aug 15, 2023 05:22am

The device maker, which grew profits but saw a margin squeeze, is forecasting a boost this year.

Source:The Australian Financial Review
Banks and tech stocks lift Australian shares; CSL, Cochlear rally on strong earnings
Aug 15, 2023 04:57am

Australian shares rose on Tuesday, helped by the gains in banks and technology stocks, while healthcare stocks CSL and Cochlear rallied after recording higher annual earnings. The S&P/ASX 200 index climbed 0.3% to 7,300.7 by 0046 GMT, its biggest intraday gain since Aug. 8. The benchmark ended down 0.9% on Monday. On the domestic bourse, banks rose 0.4%. The “big four” banks advanced between 0.1% and 1.3%. National Australia Bank said its third-quarter margins declined due to increased home lending competition and higher deposit costs. Its shares, however, inched up 1.3%. Technology stocks rose 1.2%, tracking an overnight Wall Street rebound in peers. Australia shares set for worst day in nearly 2 weeks as banks, miners weigh Heavyweights Xero and ASX-listed shares of Block gained 0.9% and 0.7%, respectively. Gold stocks, on the other hand, extended losses, falling 0.8% as a stronger dollar took the shine off bullion, while investors awaited fresh catalysts to gauge the downside risks after mixed US inflation numbers last week.

Source:Business Recorder
ASX futures flat; S&P 500 up; Cochlear, Sims, Treasury Wines to report
Aug 14, 2023 17:36pm

Australian shares were poised for a quiet open. Techs recovered in New York. China data dump at 12pm AEST. $A steady, near US65¢.

Source:The Australian Financial Review